Switch theme
Sign up to access all valuation multiples
Fagron SA is a pharmaceutical compounding company operating in Belgium. It acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company also produces pharmaceutical raw materials, equipment, and supplies that are needed to prepare medication in the pharmacy. Its segments are namely Fagron Europe, Middle East and Africa (EMEA), Fagron North America, and Fagron Latin America. The majority of its revenue comes from Fagron North America.
1990
4.0K+
LTM Revenue $1.0B
LTM EBITDA $202M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fagron has a last 12-month revenue (LTM) of $1.0B and a last 12-month EBITDA of $202M.
In the most recent fiscal year, Fagron achieved revenue of $979M and an EBITDA of $178M.
Fagron expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fagron valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | XXX | $979M | XXX | XXX | XXX |
| Gross Profit | $634M | XXX | $444M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $202M | XXX | $178M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $156M | XXX | $151M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $105M | XXX | $90.5M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $254M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fagron's stock price is EUR 22 (or $24).
Fagron has current market cap of EUR 1.6B (or $1.8B), and EV of EUR 1.8B (or $2.1B).
See Fagron trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $1.8B | XXX | XXX | XXX | XXX | $1.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fagron has market cap of $1.8B and EV of $2.1B.
Fagron's trades at 2.1x EV/Revenue multiple, and 11.7x EV/EBITDA.
Equity research analysts estimate Fagron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fagron has a P/E ratio of 16.9x.
See valuation multiples for Fagron and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 11.7x | XXX | XXX | XXX |
| EV/EBIT | 13.3x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.9x | XXX | 19.6x | XXX | XXX | XXX |
| EV/FCF | 27.1x | XXX | 26.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFagron's last 12 month revenue growth is 8%
Fagron's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Fagron's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fagron's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fagron and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fagron acquired XXX companies to date.
Last acquisition by Fagron was XXXXXXXX, XXXXX XXXXX XXXXXX . Fagron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fagron founded? | Fagron was founded in 1990. |
| Where is Fagron headquartered? | Fagron is headquartered in Belgium. |
| How many employees does Fagron have? | As of today, Fagron has 4.0K+ employees. |
| Who is the CEO of Fagron? | Fagron's CEO is Mr. Rafael Padilla. |
| Is Fagron publicy listed? | Yes, Fagron is a public company listed on BRU. |
| What is the stock symbol of Fagron? | Fagron trades under FAGR ticker. |
| When did Fagron go public? | Fagron went public in 2007. |
| Who are competitors of Fagron? | Similar companies to Fagron include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Fagron? | Fagron's current market cap is $1.8B |
| What is the current revenue of Fagron? | Fagron's last 12 months revenue is $1.0B. |
| What is the current revenue growth of Fagron? | Fagron revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Fagron? | Current revenue multiple of Fagron is 2.0x. |
| Is Fagron profitable? | Yes, Fagron is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fagron? | Fagron's last 12 months EBITDA is $202M. |
| What is Fagron's EBITDA margin? | Fagron's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Fagron? | Current EBITDA multiple of Fagron is 10.3x. |
| What is the current FCF of Fagron? | Fagron's last 12 months FCF is $76.5M. |
| What is Fagron's FCF margin? | Fagron's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Fagron? | Current FCF multiple of Fagron is 27.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
